{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:25:16Z","timestamp":1740147916705,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T00:00:00Z","timestamp":1621728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T00:00:00Z","timestamp":1621728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Impaired cardiac adrenergic activity has been demonstrated in heart failure (HF) and in diabetes mellitus (DM). [<jats:sup>123<\/jats:sup>I]I-metaiodobenzylguanidine (MIBG) enables assessment of the cardiac adrenergic nervous system. Tomographic imaging of the heart is expected to be superior to planar imaging. This study aimed to determine the quality and utility of MIBG SPECT in the assessment of cardiac innervation in postinfarction HF patients without DM, qualified for implantable cardioverter defibrillator (ICD) in primary prevention of sudden cardiac death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consecutive patients receiving an ICD on the basis of contemporary guidelines were prospectively included. Planar MIBG studies were followed by SPECT. The essential analysis was based on visual assessment of the quality of SPECT images (\u201chigh\u201d, \u201clow\u201d or \u201cunacceptable\u201d). The variables used in the further analysis were late summed defect score for SPECT images and heart-to-mediastinum rate for planar images. MIBG images were assessed independently by two experienced readers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty postinfarction nondiabetic HF subjects were enrolled. In 13 patients (26%), the assessment of SPECT studies was impossible. In addition, in 13 of 37 patients who underwent semiquantitative SPECT evaluation, the assessment was equivocal. Altogether, in 26\/50 patients (52%, 95% confidence interval 38\u201365%), the quality of SPECT images was unacceptable or low and was limited by low MIBG cardiac uptake and by comparatively high, interfering MIBG uptake in the neighboring structures (primarily, in the lungs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The utility of MIBG SPECT imaging, at least with conventional imaging protocols, in the qualification of postinfarction HF patients for ICD, is limited. In approximately half of the postinfarction HF patients, SPECT assessment of cardiac innervation can be impossible or equivocal, even without additional damage from diabetic cardiac neuropathy. The criteria predisposing the patient to good-quality MIBG SPECT are: high values of LVEF from the range characterizing the patients qualified to ICD (i.e., close to 35%) and left lung uptake intensity in planar images comparable to or lower than heart uptake.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s12149-021-01628-1","type":"journal-article","created":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T08:02:30Z","timestamp":1621756950000},"page":"916-926","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality and utility of [123I]I-metaiodobenzylguanidine cardiac SPECT imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5047-121X","authenticated-orcid":false,"given":"Anna","family":"Teresi\u0144ska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olgierd","family":"Wo\u017aniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Maci\u0105g","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Wnuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaros\u0142aw","family":"Jezierski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneta","family":"Fronczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta Katarzyna","family":"Biernacka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,23]]},"reference":[{"key":"1628_CR1","first-page":"129","volume":"22","author":"RC Kline","year":"1981","unstructured":"Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, Beierwaltes WH. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22:129\u201332.","journal-title":"J Nucl Med"},{"key":"1628_CR2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/CIRCRESAHA.113.300308","volume":"113","author":"A Lymperopoulos","year":"2013","unstructured":"Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure pathophysiology and therapy. Circ Res. 2013;113:739\u201353.","journal-title":"Circ Res"},{"key":"1628_CR3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0002-8703(05)80183-8","volume":"119","author":"K Nakajima","year":"1990","unstructured":"Nakajima K, Bunko H, Taki J, Shimizu M, Muramori A, Hisada K. Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J. 1990;119:1329\u201337.","journal-title":"Am Heart J"},{"key":"1628_CR4","first-page":"251","volume-title":"Autonomic innervation of the heart","author":"HJ Verberne","year":"2015","unstructured":"Verberne HJ, Scholte AJHA. General principles of [123I]-MIBG scintigraphy for the assessment of the cardiac symphatetic activity: from planar to SPECT. In: Slart RHJA, Tio RE, Elsinga PH, Schwaiger M, editors. Autonomic innervation of the heart. Heidelberg: Springer; 2015. p. 251\u2013306."},{"key":"1628_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12350-011-9438-0","volume":"19","author":"J Chen","year":"2012","unstructured":"Chen J, Folks RD, Verdes L, Manatunga DN, Jacobson AF, Garcia EV. Quantitative I-123 mIBG SPECT in differentiating abnormal and normal mIBG myocardial uptake. J Nucl Cardiol. 2012;19:92\u20139.","journal-title":"J Nucl Cardiol"},{"key":"1628_CR6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s12350-012-9539-4","volume":"19","author":"B Van der Veen","year":"2012","unstructured":"Van der Veen B, Younis IA, de Roos A, Stokkel MPM. Assessment of global cardiac I-123 MIBG uptake and washout using volumetric quantification of SPECT acquisitions. J Nucl Cardiol. 2012;19:752\u201362.","journal-title":"J Nucl Cardiol"},{"key":"1628_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCIMAGING.108.782433","volume":"1","author":"JJ Bax","year":"2008","unstructured":"Bax JJ, Kraft O, Buxton AE, Fjeld JG, Parizek P, Agostini D, et al. 123-MIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing. A prospective multicenter pilot study. Circ Cardiovasc Imaging. 2008;1:131\u201340.","journal-title":"Circ Cardiovasc Imaging"},{"key":"1628_CR8","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/j.jacc.2009.12.066","volume":"55","author":"MJ Boogers","year":"2010","unstructured":"Boogers MJ, Borleffs CJW, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010;55:2769\u201377.","journal-title":"J Am Coll Cardiol"},{"key":"1628_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s12350-014-9911-7","volume":"21","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Zhou W, Folks RD, Manatunga DN, Jacobson AF, Bax JJ, et al. I-123 mIBG and Tc-99m myocardial SPECT imaging to predict inducibility of ventricular arrhythmia on electrophysiology testing: a retrospective analysis. J Nucl Cardiol. 2014;21:913\u201320.","journal-title":"J Nucl Cardiol"},{"key":"1628_CR10","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1161\/01.CIR.75.4.877","volume":"75","author":"H Inoue","year":"1987","unstructured":"Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart: supersensitivity that may be arrhythmogenic. Circulation. 1987;75:877\u201387.","journal-title":"Circulation"},{"key":"1628_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s12350-015-0105-8","volume":"23","author":"MI Travin","year":"2016","unstructured":"Travin MI. It\u2019s not all in the numbers. J Nucl Cardiol. 2016;23:436\u201341.","journal-title":"J Nucl Cardiol"},{"key":"1628_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/CIRCEP.114.002105","volume":"8","author":"T Klein","year":"2015","unstructured":"Klein T, Abdulghani M, Smith M, Huang R, Asoglu R, Remo BF, et al. Three-dimensional 123I-Meta-Iodobenzylguanidine cardiac innervation maps to assess substrate and successful ablation sites for ventricular tachycardia. Feasibility study for a novel paradigm of innervation imaging. Circ Arrhythm Electrophysiol. 2015;8:583\u201391.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1628_CR13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2337\/diab.41.9.1069","volume":"41","author":"M Mantysaari","year":"1992","unstructured":"Mantysaari M, Kuikka M, Mustonen J, Tahvanainnen K, Vanninen E, Lansimies E, Usitupa M. Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I] metaiodobenzylguanidine. Diabetes. 1992;41:1069\u201375.","journal-title":"Diabetes"},{"key":"1628_CR14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/0735-1097(94)00459-4","volume":"25","author":"A Langer","year":"1995","unstructured":"Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol. 1995;25:610\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1628_CR15","first-page":"1985","volume":"37","author":"N Hattori","year":"1996","unstructured":"Hattori N, Tamaki N, Hayashi T, Masuda I, Kudoh T, Tateno M, et al. Regional abnormality of iodine-123-MIBG in diabetic hearts. J Nucl Med. 1996;37:1985\u201390.","journal-title":"J Nucl Med"},{"key":"1628_CR16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/00006231-199708000-00010","volume":"18","author":"H Nagaoka","year":"1997","unstructured":"Nagaoka H, Iizuka T, Kubota S, Kato N, Suzuki T, Inoue T, et al. Depressed contractile response to diabetic patients in the absence of cardiovascular disease: Relationship to adrenergic cardiac dysinnervation. Nucl Med Commun. 1997;18:761\u201370.","journal-title":"Nucl Med Commun"},{"key":"1628_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.nuclcard.2005.11.009","volume":"13","author":"S Nagamachi","year":"2006","unstructured":"Nagamachi S, Fujita S, Nishii R, Futami S, Tamura S, Mizuta M, et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with noninsulin-dependent diabetes mellitus. J Nucl Cardiol. 2006;13:34\u201342.","journal-title":"J Nucl Cardiol"},{"key":"1628_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/CIRCIMAGING.110.954784","volume":"4","author":"MC Gerson","year":"2011","unstructured":"Gerson MC, Caldwell JH, Ananthasubramanian K, Clements IP, Henzlova MJ, Amanullah A, Jacobson AF. Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients. Circ Cardiovasc Imaging. 2011;4:87\u201393.","journal-title":"Circ Cardiovasc Imaging"},{"key":"1628_CR19","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.2337\/dc12-2147","volume":"36","author":"S Paolillo","year":"2013","unstructured":"Paolillo S, Rengo G, Pagano G, Pellegrino T, Savarese G, Frmminella GD, et al. Impact of diabetes mellitus on cardiac sympathetic innervation in patients with heart failure. Diabetes Care. 2013;36:2395\u2013401.","journal-title":"Diabetes Care"},{"key":"1628_CR20","first-page":"74","volume":"35","author":"P Garcia-Gonzalez","year":"2016","unstructured":"Garcia-Gonzalez P, Fabregat-Andres O, Cozar-Santiago P, Sanchez-Jurado R, Estronell-Eril J, Valle-Munoz A, et al. Cardiac sympathetic innervation assessed with 123 I-MIBG retains prognostic utility in diabetic patients with severe left ventricular dysfunction evaluated for primary prevention implantable cardioverter-defibrillator. Rev Esp Med Nucl Imagen Mol. 2016;35:74\u201380.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"1628_CR21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-3-662-45074-1_15","volume-title":"Autonomic innervation of the heart","author":"AJHA Scholte","year":"2015","unstructured":"Scholte AJHA, Verberne HJ. Imaging the cardiac autonomic nervous system in diabetes mellitus. In: Slart RHJA, Tio RE, Elsinga PH, Schwaiger M, editors. Autonomic innervation of the heart. Heidelberg: Springer; 2015. p. 309\u201320."},{"key":"1628_CR22","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.jacc.2010.01.014","volume":"55","author":"AF Jacobson","year":"2010","unstructured":"Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"1628_CR23","first-page":"e240","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240\u2013327.","journal-title":"Circulation"},{"key":"1628_CR24","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"1628_CR25","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s00259-010-1491-4","volume":"37","author":"A Flotats","year":"2010","unstructured":"Flotats A, Carrio I, Agostini D, Le Guludec D, Marcassa C, Schaffers M, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1628_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"8","author":"JM Bland","year":"1986","unstructured":"Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;8:307\u201310.","journal-title":"Lancet"},{"key":"1628_CR27","first-page":"334","volume":"39","author":"S Murashima","year":"1998","unstructured":"Murashima S, Takeda K, Matsumura K, Yamakado K, Sakuma H, Kitano T, et al. Increased lung uptake of iodine-123-MIBG in diabetics with sympathetic nervous dysfunction. J Nucl Med. 1998;39:334\u20138.","journal-title":"J Nucl Med"},{"key":"1628_CR28","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1111\/jgh.15096","volume":"35","author":"AF Jacobson","year":"2020","unstructured":"Jacobson AF, Matsuoka DT. Noradrenergic uptake in the liver on 123I-mIBG imaging: influence of heart failure and diabetes. J Gastroenterol Hepatol. 2020;35:2151\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"1628_CR29","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/0002-8703(93)91056-K","volume":"126","author":"JS Gill","year":"1993","unstructured":"Gill JS, Hunter GJ, Gane G, Camm AJ. Heterogenity of the human myocardial sympathetic innervation: in vivo demonstration by iodine 123-labeled metaiodobenzylguanidine scintigraphy. Am Heart J. 1993;126:390\u20138.","journal-title":"Am Heart J"},{"key":"1628_CR30","doi-asserted-by":"publisher","first-page":"25S","DOI":"10.2967\/jnumed.115.157503","volume":"56","author":"AC Dimitriu-Leen","year":"2015","unstructured":"Dimitriu-Leen AC, Scholte AJHA, Jacobson AF. 123I-MIBG SPECT for evaluation of patients with heart failure. J Nucl Med. 2015;56:25S-30S.","journal-title":"J Nucl Med"},{"key":"1628_CR31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.semnuclmed.2014.04.005","volume":"44","author":"MI Travin","year":"2014","unstructured":"Travin MI. Cardiac radionuclide imaging to assess patients with heart failure. Semin Nucl Med. 2014;44:294\u2013313.","journal-title":"Semin Nucl Med"},{"key":"1628_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12350-015-0336-8","volume":"24","author":"MI Travin","year":"2017","unstructured":"Travin MI, Henzlova MJ, van Eck-Smit BLV, Jain D, Carrio I, Folks RD, et al. Assessment of 123I-mIBG and 99mTc-tetrofosmin single-photon emission computed tomographic images for the prediction of arrhythmic events in patients with ischemic heart failure: intermediate severity innervation defects are associated with higher arrhythmic risk. J Nucl Cardiol. 2017;24:377\u201391.","journal-title":"J Nucl Cardiol"},{"key":"1628_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12350-017-0913-0","volume":"26","author":"H Yamamoto","year":"2019","unstructured":"Yamamoto H, Yamada T, Tamaki S, et al. Prediction of sudden cardiac death in patients with chronic heart failure by regional washout rate in cardiac MIBG SPECT imaging. J Nucl Cardiol. 2019;26:109\u201317.","journal-title":"J Nucl Cardiol"},{"key":"1628_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s12350-015-0097-4","volume":"23","author":"IP Clements","year":"2016","unstructured":"Clements IP, Garcia EV, Chen J, Folks RD, Butler J, Jacobson AF, et al. Quantitative iodine-123-metaiodobenzoqanidine (MIBG) SPECT imaging in heart failure with left ventricular systolic dysfunction: development and validation of automated procedures in conjunction with technetium-99m tetrofosmin myocardial perfusion SPECT. J Nucl Cardiol. 2016;23:425\u201335.","journal-title":"J Nucl Cardiol"},{"key":"1628_CR35","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00259-013-2461-4","volume":"40","author":"T Pellegrino","year":"2013","unstructured":"Pellegrino T, Petretta M, De Luca S, Paolillo S, Boemio A, Carotenuto R, et al. Observer reproducibility of results from a low-dose 123I-metaiodobenzylguanidine cardiac imaging protocol in patients with heart failure. Eur J Nucl Med Mol Imaging. 2013;40:1549\u201357.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1628_CR36","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s12350-018-1258-z","volume":"26","author":"G De Vincentis","year":"2019","unstructured":"De Vincentis G, Frantellizzi V, Fedele F, Farcomeni A, Scarparo P, Salvi N, et al. Role of cardiac 123I-mIBG imaging in predicting arrhythmic events in CHF patients with ICD implantation. J Nucl Cardiol. 2019;26:1188\u201396.","journal-title":"J Nucl Cardiol"},{"key":"1628_CR37","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.ijcard.2012.12.077","volume":"168","author":"S Rispler","year":"2013","unstructured":"Rispler S, Frenkel A, Kuptzov E, Brodov Y, Israel O, Keidar Z, et al. Quantitative 123 I-MIBG SPECT\/CT assessment of cardiac sympathetic innervations\u2014a new diagnostic tool for heart failure. Int J Cardiol. 2013;168:1556\u20138.","journal-title":"Int J Cardiol"},{"key":"1628_CR38","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1007\/s00259-009-1093-1","volume":"36","author":"HJ Verberne","year":"2009","unstructured":"Verberne HJ, Somsen GA, Povinec P, van Eck-Smit BL, Jacobson AF. Impact of mediastinal, liver and lung 123I-metaiodobenzylguanidine (123I-MIBG) washout on calculated 123I-MIBG myocardial washout. Eur J Nucl Med Mol Imaging. 2009;36:1322\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1628_CR39","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s12350-017-1183-6","volume":"26","author":"T Bateman","year":"2019","unstructured":"Bateman T, Ananthasubramaniam K, Berman D, Gerson M, Gropler R, Henzlova M, et al. Reliability of the 123I-mIBG heart\/mediastinum ratio: results of a multicenter test\u2013retest reproducibility study. J Nucl Cardiol. 2019;26:1555\u201365.","journal-title":"J Nucl Cardiol"},{"key":"1628_CR40","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00259-012-2180-2","volume":"39","author":"CE Veltman","year":"2012","unstructured":"Veltman CE, Boogers MJ, Meinardi JE, Al Younis I, Dibbets-Schneider P, Van der Wall EE, et al. Reproducibility of planar (123)I-meta-iodobenzylguanidine (mIBG) myocardial scintigraphy in patients with heart failure. Eur J Nucl Med Mol Imaging. 2012;39:1599\u2013608.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1628_CR41","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/01.CIR.78.4.1008","volume":"78","author":"JD Minardo","year":"1988","unstructured":"Minardo JD, Tuli MM, Mock BH, Weiner RE, Pride HP, Wellmann HN, et al. Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation. 1988;78:1008\u201319.","journal-title":"Circulation"},{"key":"1628_CR42","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s12350-010-9292-5","volume":"17","author":"JA Fallavolita","year":"2010","unstructured":"Fallavolita JA, Canty JM Jr. Dysinnervated but viable myocardium in ischemic heart disease. J Nucl Cardiol. 2010;17:1107\u201315.","journal-title":"J Nucl Cardiol"},{"key":"1628_CR43","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3109\/0284186X.2011.580001","volume":"50","author":"BF Hutton","year":"2011","unstructured":"Hutton BF. Recent advances in iterative reconstruction for clinical SPECT\/PET and CT. Acta Oncol. 2011;50:851\u20138.","journal-title":"Acta Oncol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01628-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-021-01628-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01628-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T01:55:48Z","timestamp":1699062948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-021-01628-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,23]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1007\/s12149-021-01628-1","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"type":"print","value":"0914-7187"},{"type":"electronic","value":"1864-6433"}],"subject":[],"published":{"date-parts":[[2021,5,23]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No potential conflicts of interest were disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. Regional Bioethics Committee approval was obtained (Permission Number 1277). Informed signed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}